intervals (CI): 1.5-3.9] [6] . In the same study, we found that another haplotype (FGG-H3) was associated with a slight reduction in risk [odds ratio (OR) ¼ 0.8, 95% CI: 0.6-1.0]. None of these haplotypes was associated with total fibrinogen levels. However, the FGG-H2 haplotype was associated with reduced levels of fibrinogen c¢, a product of alternative splicing of the FGG gene. In a recent report, Mannila et al. [8] studied the effect of haplotypes across the fibrinogen gene cluster on the risk of myocardial infarction (MI). They determined the *216C > T polymorphism, which is identical to FGG-H2 tagging SNP 10034 C/T [rs2066865]. In their study, the FGG-H2 haplotype was not associated with the risk of MI. However, they found a significant difference in the frequency distribution of the minor allele of the 1299 + 79T > C polymorphism between patients and controls (0.294 vs. 0.342, P ¼ 0.04), which suggests that this haplotype might be protective against the development of MI. This polymorphism is identical to FGG-H3 tagging SNP 9340 T/C [rs1049636].
The aim of the present study was to investigate the effect of the four most common haplotypes of the FGG gene on the risk of MI. For this study, a large population-based case-control study, ÔStudy of Myocardial Infarctions LeidenÕ (SMILE) was used. Full details of the SMILE study have been described elsewhere [9] . The subjects used in our previous study on venous thrombosis [6] were all of Dutch origin and four common haplotypes of the fibrinogen gamma gene were present in this population. Because the subjects of the SMILE study were all Dutch men, we assumed that in the SMILE population only these four common haplotypes would be present. To tag these four common haplotypes, all subjects were genotyped for three haplotype-tagging polymorphisms by the 5¢ nuclease/TaqMan assay [10] . Polymorphism 10034 C/T [rs2066865] tagged FGG-H2, polymorphism 9340 T/C [rs1049636] tagged FGG-H3 and polymorphism 5836 G/A [rs2066860] tagged FGG-H4 [6] . FGG-H1 consisted of the common alleles of the three-mentioned polymorphisms. (Position numbering according to SeattleSNPs [11] , GenBank Accession number AF350254). The distribution of the genotypes among control subjects was as expected for a population in Hardy-Weinberg equilibrium. No haplotypes could be assigned to four patients and two control subjects, because of intragenic recombination. These samples were excluded from the analyses. As shown in Table 1 , overall none of the haplotypes of the FGG gene was associated with the risk of MI, including FGG-H2, which we found to be a risk factor for venous thrombosis [6] . The allele frequency of FGG-H2 was 0.276 in cases and 0.277 in control subjects. This is in agreement with the data of Mannila et al. [8] , who did not find an association in 377 MI patients and 387 control subjects aged <60 years in Sweden. However, we could not confirm the reduction in risk for FGG-H3 found by Mannila et al. We found allele frequencies of 0.298 and 0.284 for patients and control subjects, respectively (Table 1) .
Most patients with MI are middle-aged or elderly. Those suffering MI at a younger age usually have an excess of risk factors, including genetic factors. In men below the age of 50 (150 patients and 158 control subjects), the risk of MI was slightly decreased for FGG-H1 (Table 1) and slightly increased for FGG-H2. There was no effect on risk for FGG-H3 and FGG-H4. For men aged 50 or above, there was no effect on risk in any of the haplotypes. So, we only found a slight increase in risk for FGG-H2 in men below the age of 50. This might be an indication that FGG-H2 not only affects venous thrombosis risk, but also the risk of myocardial infarction, although the effect was weak (OR for FGG-H2H2 carriers 1.5) with a wide CI (0.7-3.5). The sample size of this young subgroup was relatively small and it would be useful to investigate the role of FGG-H2 in a larger study of patients with myocardial infarction at a young age.
Furthermore, we investigated the combined effect of FGG haplotypes and cardiovascular risk factors such as smoking (345 patients and 214 control subjects) or metabolic risk factors (203 patients and 197 control subjects), in which having a metabolic risk factor was defined as the presence of obesity, diabetes, hypertension or hypercholesterolemia [9] . The risks of the four haplotypes in the different subgroups with or without the cardiovascular risk factors did not change compared with the risks in the overall population. In fact, the risks did not exceed that of the single effects of the cardiovascular risk factors, so we did not find evidence for synergistic effects between FGG haplotypes and cardiovascular risk factors.
In addition, we studied the relation between the FGG haplotypes and fibrinogen levels. In the control subjects, fibrinogen levels were measured in plasma using the Clauss thrombin time method as described previously [12] . We did not observe an association of FGG haplotypes with fibrinogen Letters to the Editor 475 levels in these control subjects. This is consistent with a previous study in which we did not find an association of these haplotypes with fibrinogen levels in the 473 control subjects of the Leiden Thrombophilia Study [6] . We conclude that none of the four common haplotypes of the FGG gamma gene has a strong effect on the risk of MI. Homozygosity for FGG-H2, which we found previously to be a risk factor for venous thrombosis, might slightly increase the risk of MI in patients younger than 50 years. These findings are in line with the studies on other prothrombotic factors that affect the risk of venous thrombosis but have small or no effects on arterial disease [13] .
